logo

Halozyme Therapeutics, Inc. (HALO)



Trade HALO now with
  Date
  Headline
11/13/2019 11:26:28 PM Halozyme Therapeutics Announces Pricing Of Private Offering Of $400 Mln Of Convertible Senior Notes Due 2024
11/4/2019 7:16:13 AM Halozyme Initiates Organizational Restructuring To Close Oncology Operations, Reducing Headcount By About 55%
9/13/2019 1:05:16 AM Halozyme Therapeutics Says Global Phase III FeDeriCa Study Conducted By Genentech Meets Primary Endpoint
7/19/2019 7:07:13 AM Halozyme: Janssen Submits Extension Application To EMA For Subcutaneous Formulation Of DARZALEX Using ENHANZE Technology
7/17/2019 8:05:14 AM Halozyme Says First Clinical Dosing In Argenx's Phase 1 Trial Of Efgartigimod With ENHANZE Drug Delivery Technology
6/25/2019 8:07:35 AM Halozyme Reports CRADA With National Institute Of Allergy And Infectious Diseases For Use Of ENHANZE Drug Delivery Tech
5/22/2019 1:07:27 AM Halozyme Says Argenx Selected Second Target Under ENHANZE Technology Collaboration And License Agreement
5/7/2019 4:09:30 PM Halozyme Q1 EPS $0.01 Vs. Loss $0.19 Year Ago
2/28/2019 12:21:01 PM Halozyme Announces FDA Approval Of Herceptin Hylecta
2/21/2019 4:04:13 PM Halozyme Q4 Loss/share $0.01 Vs. Profit $0.85 Year Ago
10/25/2018 8:08:07 AM Halozyme Reports First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of BMS-986179 With Enhanze Technology
9/17/2018 8:11:11 AM Halozyme Reports Approval Of Subcutaneous Formulation Of Trastuzumab In Canada
9/10/2018 8:02:16 AM Halozyme Appoints Bernadette Connaughton To Board
7/26/2018 8:11:36 AM Halozyme Says Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using ENHANZE Technology
7/11/2018 8:34:35 AM Halozyme : FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
  
 
>